0.860USD+0.860æéå€ååŒÂ 07/31, 20:00 (ET)
907.03KæäŸ¡ç·é¡
æå€±é¡çŽè¿12ã¶æPER
äž»èŠããŒã¿
0.950å§å€
0.950é«å€
111.64Kåºæ¥é«
æå€±é¡çŽè¿12ã¶æPER
--äºæ³PER
--çŽè¿12ã¶æé
åœ
10.79%売買å転ç
0.929忥çµå€
0.870å®å€
67.28K売買代é
æå€±é¡æ ªäŸ¡åçç
0.22PBRïŒæ ªäŸ¡çŽè³ç£åçïŒ
0.00%çŽè¿12ã¶æé
åœå©åã
-126.94%ç·è³ç£å©çç
16.68052é±é«å€
0.41åºæ¥é«æ¯ç%
-34.16MçŽå©ç
1.03Mæ ªåŒæ°
-49.49301æ ªåœããå©çïŒEPSïŒ
0.81ããŒã¿å€
-171.56%èªå·±è³æ¬å©çç
1.62352é±å®å€
8.61%æ¯ãå¹
19.64%ç²å©çç
907.03KæäŸ¡ç·é¡
-2.72ãªã¹ã¯ãªã¿ãŒã³
6.79%ãªã¹ã¯ç
é貚: USD æŽæ°æå»: 2026-07-31 äž»èŠã€ã³ãµã€ã
Bluejay Diagnostics Incã®ãã¡ã³ãã¡ã³ã¿ã«ãºã¯æ¯èŒçéåžžã«å¥å
šã§ããæé·ã®å¯èœæ§ã¯é«ãã§ããããªã¥ãšãŒã·ã§ã³ã¯é©æ£äŸ¡æ Œãšè©äŸ¡ãããŠããŸãããã€ãªãã¯ãããžãŒ & å»çç ç©¶æ¥çã§ã®é äœã¯385äž187äœã§ããæ©é¢æè³å®¶ä¿æçã¯éåžžã«é«ãã§ããäžæçã«ã¯ãæ ªäŸ¡ã¯äžéãã¬ã³ããšäºæ³ãããŸããæ ªåŒåžå Žã§ã®ããã©ãŒãã³ã¹ã¯ãã®1ãæã§éåžžã«äœèª¿ã§ããããå瀟ã®ãã¡ã³ãã¡ã³ã¿ã«ãºãšãã¯ãã«ã«ã¯å
調ã§ããæ ªäŸ¡ã¯æ¯æç·ã𿵿ç·ã®éã§æšªã°ãæšç§»ããŠãããã¬ã³ãžçžå Žã§ã®ã¹ã€ã³ã°ãã¬ãŒãã«é©ããŠããŸãã
Bluejay Diagnostics Incã®ã¹ã³ã¢î°î°
ãµããŒãã©ã€ã³ãšã¬ãžã¹ã¿ã³ã¹ã©ã€ã³

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
éåžžã«äœã
éåžžã«é«ã
Bluejay Diagnostics Incã®æ³šç®ãã€ã³ã
匷ã¿ãªã¹ã¯
Bluejay Diagnostics Inc ãã¥ãŒã¹
ææ°æ
å ±ããåŸ
ã¡ãã ãã...
ææšî
ææš
売ã(3)
äžç«(2)
è²·ã(0)
ç§»åå¹³å
売ã(6)
äžç«(0)
è²·ã(0)
è²¡åææšî
EPS

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
ç·å£²äžé«

äŒç€Ÿããé¢é£ããŒã¿ããŸã é瀺ãããŠããŸããã
Bluejay Diagnostics Incã®äŒæ¥æ
å ±î
Bluejay Diagnostics, Inc. is a medical diagnostics company focused on improving patient outcomes in critical care settings. It develops rapid tests using whole blood on its Symphony technology platform (Symphony), which consists of an analyzer and single-use protein detection cartridges that have the function of automatic stepwise feeding of reagent. The Symphony device is designed to produce laboratory-quality results in 20 minutes in critical care settings, including Intensive Care Units (ICUs) and Emergency Rooms (ERs). Its product candidate, the Symphony IL-6 test, is an immunoassay for the measurement of interleukin-6 (IL-6) to be used for the monitoring of disease progression in critical care settings. It is focused on pursuing the Symphony IL-6 test in the context of sepsis. IL-6 is a clinically established inflammatory biomarker, and is considered a 'first-responder', for the assessment of severity of infection and inflammation across many disease indications, including sepsis.
äŒæ¥ã³ãŒãBJDX
äŒæ¥åBluejay Diagnostics Inc
æé«çµå¶è²¬ä»»è
ãCEOãDey (Neil)
ãŠã§ããµã€ãhttps://bluejaydx.com/
æ ªäž»çµ±èšî
ãããã質å
Bluejay Diagnostics IncïŒBJDXïŒã®çŸåšã®æ ªäŸ¡ã¯ãããã§ããïŒ
îBluejay Diagnostics IncïŒBJDXïŒã®çŸåšã®æ ªäŸ¡ã¯0.88ã§ãã
Bluejay Diagnostics Incã®ãã£ãã«ãŒã·ã³ãã«ã¯äœã§ããïŒ
îBluejay Diagnostics Incã®ãã£ãã«ãŒã·ã³ãã«ã¯BJDXã§ãã
Bluejay Diagnostics Incã®52é±é«å€ã¯ãããã§ããïŒ
îBluejay Diagnostics Incã®52é±é«å€ã¯16.68ã§ãã
Bluejay Diagnostics Incã®52é±å®å€ã¯ãããã§ããïŒ
îBluejay Diagnostics Incã®52é±å®å€ã¯1.62ã§ãã
Bluejay Diagnostics Incã®æäŸ¡ç·é¡ã¯ãããã§ããïŒ
îBluejay Diagnostics Incã®æäŸ¡ç·é¡ã¯907.03Kã§ãã
Bluejay Diagnostics Inc (BJDX) ã®1æ ªåœããå©çïŒEPS TTMïŒã¯ãããã§ããïŒ
îBluejay Diagnostics IncïŒBJDXïŒã®1æ ªåœããå©çïŒEPS TTMïŒã¯-61.01ã§ãã